The global plasma fractionation market was valued at $27.2 billion in 2022 and $29.0 billion in 2023. It is projected to grow at a 6.9% CAGR to reach $40.4 billion by 2028.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93798284
What are the key drivers influencing the growth of the Plasma Fractionation Market?
The global plasma fractionation market is primarily driven by the increasing use of immunoglobulins across various therapeutic areas and the strategic expansion of plasma collection centers and inventories by key market players. Another significant driver is the rising prevalence of respiratory diseases and Alpha-1-antitrypsin deficiency (AATD), which has spurred demand for protease inhibitors like alpha-1-antitrypsin for treating lung and hepatic diseases. Furthermore, improvements in diagnostic techniques and supportive government strategies aimed at increasing regional self-sufficiency in plasma production are expected to further propel market growth.
What are the major restraints limiting the growth of the Plasma Fractionation Market?
The growth of the plasma fractionation market is primarily restrained by high costs and limited reimbursement for plasma products. Additionally, the market faces significant disruption from recombinant alternatives, such as AFSTYLA and VONVENDI, which are gaining traction in developed and emerging economies like Brazil, India, and Russia. These factors are expected to limit the expansion of plasma-derived coagulation factors during the forecast period.
What emerging opportunities are expected to shape the future of the Plasma Fractionation Market?
The implementation of government strategies aimed at increasing regional self-sufficiency serves as a significant opportunity for the plasma fractionation market. These initiatives are designed to strengthen domestic production and reduce dependence on imported plasma and plasma-derived medicinal products, particularly from the United States. Recent policy changes, such as the UK lifting its ban on domestic blood plasma for clinical use and ongoing revisions to the EU Blood, Tissues, and Cells regulation, are expected to increase local plasma collection and fractionation rates to meet patient demands.
What are the critical challenges faced by stakeholders in the Plasma Fractionation Market?
The plasma fractionation market faces significant challenges due to stringent government regulations focused on ensuring the safety and quality of products, which can act as a barrier to entry for new and smaller players. These regulations require regular inspections of sourced plasma and adherence to strict WHO guidelines regarding pathogen transmission risks. Additionally, regional restrictions, such as China’s long-standing ban on most imported plasma products, and the logistical complexity of maintaining a large, highly trained workforce further hamper international expansion and market growth.
What are the key segments of the Plasma Fractionation Market based on type, application, and end user?
The global plasma fractionation market is categorized into various submarkets to provide a comprehensive analysis of its revenue and trends. By product, the market includes immunoglobulins (such as intravenous and subcutaneous), coagulation factor concentrates (including Factor VIII and Von Willebrand Factor), albumin, and protease inhibitors. Applications of these products span multiple medical fields, including neurology, immunology, hematology, critical care, and pulmonology. The primary end users are hospitals, clinics, clinical research laboratories, and academic institutes. Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, with the Asia Pacific region expected to exhibit the highest growth rate during the forecast period.
Which regions are dominating and emerging in the Plasma Fractionation Market?
The plasma fractionation market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Asia Pacific is identified as the fastest-growing regional market, projected to achieve the highest CAGR between 2023 and 2028 due to increased medical research, rising use of albumin and immunoglobulins, and an emphasis on improved diagnostic and prophylactic treatments. Meanwhile, North America and Europe remain significant hubs, with the United States acting as the world’s leading provider of plasma and the UK recently lifting a long-standing ban on domestic blood plasma to increase its regional self-sufficiency. Emerging strategies in these regions aim to decrease reliance on imports and strengthen domestic production to meet local patient demands.
Request Free Pages-https://www.marketsandmarkets.com/requestsampleNew.asp?id=93798284